Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialResearch Article Published on 2024-05-062024-09-05 Journal: Pathogens and Immunity [Category] update2024, [키워드] COVID-19 monoclonal antibodies outpatient treatment SARS-CoV-2 Subcutaneous [DOI] 10.20411/pai.v9i1.660 PMC 바로가기 [Article Type] Research Article
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studiesarticle Published on 2024-01-062024-09-05 Journal: European heart journal. Cardiovascular pharmacothe [Category] update2024, [키워드] furosemide heart failure intravenous Pharmacodynamics pharmacokinetics Subcutaneous [DOI] 10.1093/ehjcvp/pvad073 PMC 바로가기 [Article Type] article
Investigating Interactions Between Endothelial Cells and Parasitized Red Blood Cells in Skin and Subcutaneous Tissuearticle Published on 2022-12-312024-09-01 Journal: Methods in molecular biology (Clifton, N.J.) [Category] 말라리아, [키워드] Culture cytoadherence Endothelium Ex vivo Host Immunophenotyping parasite Skin sequestration Subcutaneous [Article Type] article
Mass Switch From Intravenous to Subcutaneous Tocilizumab in Rheumatic Diseases During the SARS-COV-2 PandemicArticle Published on 2022-10-012022-11-15 Journal: Journal of clinical rheumatology : practical reports on rheumatic & [Category] COVID19(2023년), SARS, 진단, [키워드] administration adverse event Analysis Cell COVID Critical disease effective Follow-up Giant giant cell arteritis headache hospital injection intravenous juvenile idiopathic arthritis mass pandemic Patient remained rheumatoid arthritis rheumatological patient rheumatology Safe Subcutaneous subgroup analysis switch switching Systemic sclerosis TCZ the SARS-CoV-2 Tocilizumab Treatment was performed [DOI] 10.1097/RHU.0000000000001862 PMC 바로가기
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics2차 항체 결핍을 동반한 만성 림프구성 백혈병에서 피하 면역글로불린. Covid-19 전염병 동안의 단일 중심적 경험Article Published on 2022-08-012022-09-12 Journal: Hematological oncology [Category] MERS, 진단, [키워드] administration age antibody appear baseline CD19 CD4/CD8 chronic lymphocytic leukemia CLL Comorbidities COVID 19 deficiency dosage dose Efficacy and safety eligibility event expenditures FIVE Frequency hypogammaglobinemia IgG IgG levels immune immune dysfunction Immunoglobulin immunoglobulin replacement therapy immunoglobulins increase infections initiated interstitial pneumonia leukemia lymphocyte Pandemics Patient Prophylaxis Quality of life receiving reduced risk of infections Safe secondary secondary antibody Subcutaneous subcutaneous immunoglobulins. subset therapy treated Treatment were recorded [DOI] 10.1002/hon.2966 PMC 바로가기 [Article Type] Article
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialSARS-CoV-2 감염 외래 환자에서 Casirivimab과 Imdevimab COVID-19 항체 조합의 바이러스학적 효능: 2상 용량 범위 무작위 임상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: JAMA Network Open [Category] SARS, 임상, 진단, [키워드] 95% CI Administered age Asymptomatic average baseline Casirivimab clinical collected COVID-19 death dose double-blind Efficacy efficacy analysis greater Hispanic Hospitalization hypersensitivity reactions Imdevimab in viral intravenous mean difference monoclonal antibody combination outcome Outpatient parallel-group participant Participants Patient patients Phase 2 Phase 3 Placebo placebo-controlled primary end point Randomized randomized clinical trial ranged Reactions reduced reduction reported risk factor SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event seronegative severe COVID-19 study drug Subcutaneous symptomatic symptomatic patient The United States Treatment Viral load were excluded white [DOI] 10.1001/jamanetworkopen.2022.25411 PMC 바로가기 [Article Type] Clinical Trial
Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]염증성 장 질환 환자에서 정맥 주사에서 피하 베돌리주맙으로 전환 [TRAVELESS]Article Published on 2022-07-142022-09-12 Journal: Journal of Crohn's & colitis [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adverse drug reactions appear baseline benefit biochemical bowel calprotectin clinically Cohort cohort of patients declining Disease activity dose effective evaluate expected Health Service IBD increase in Inflammatory bowel disease injection intravenous measure offered outcome Patient Patient satisfaction reaction reason reduction reported risk factor routine clinical care Safe SARS-COV-2 infection statistically significant statistically significant difference Subcutaneous switching TRAVELESS Treatment unlikely vedolizumab Week [DOI] 10.1093/ecco-jcc/jjab224 PMC 바로가기 [Article Type] Article
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era류마티스 질환 및 염증성 장 질환에 대한 피하 인플릭시맙의 전망: COVID-19 시대 전, 중, 후Review Published on 2022-06-012022-09-12 Journal: Advances in therapy [Category] MERS, 진단, [키워드] administration anticipated approval benefit Biobetters bowel clinical advantage clinical benefit clinical trial coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 CT-P13 SC Drug administration Efficacy and safety gastroenterology Guidance hcp healthcare Healthcare professional Healthcare system Healthcare systems IBD implementation improvement Inflammatory bowel disease infliximab Innovative biologics intravenous IV infusion management Nosocomial infection offer pandemic Patient Patient care Patient satisfaction patients Physicians Potential preference provide real-world data Real-world evidence reduced reduction in Regulatory resource rheumatic disease Rheumatic diseases rheumatoid arthritis rheumatology risk selected significant changes in Subcutaneous Subcutaneous infliximab suggested Support supported switching Telemedicine therapy Treatment [DOI] 10.1007/s12325-021-01990-6 PMC 바로가기 [Article Type] Review
Immunogenicity of varicella-zoster virus vaccine by different routes of administration: Comparable vaccination efficacy of one-fifth dose intradermal vaccination to conventional subcutaneous vaccination수두-대상포진 바이러스 백신의 다양한 투여 경로에 따른 면역원성: 전통적인 피하 백신 접종에 비해 1/5 용량의 피내 백신 접종의 유사한 예방 접종 효능Article Published on 2022-05-012023-05-31 Journal: Journal of dermatological science [Category] 대상포진, 두창, 수두, 홍역, [키워드] Cell-mediated immunity herpes zoster Humoral immunity injection intradermal injection Subcutaneous Varicella-Zoster Virus [DOI] 10.1016/j.jdermsci.2022.04.001
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19카시리비맙 및 임데비맙 단클론항체의 피하 또는 정맥내 투여와 COVID-19가 있는 성인의 임상 결과와의 연관성Article Published on 2022-04-012022-09-12 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI adjusted administer Administered administration Admission adverse events age antibody association Casirivimab clinical clinically cohort study Control control group COVID-19 death decrease eligible eligible patient Emergency use authorization end point evaluate evaluated Evidence expand health system Hospitalization Imdevimab injection intensive care intravenous mAb mechanical ventilation Mild moderate Moderate COVID-19 no difference outcome Outpatient Patient patients patients treated Primary outcome prospective cohort study randomized clinical trial reduced risk risk ratio secondary single dose statistically Subcutaneous subcutaneous administration subcutaneously Symptom Symptoms Treatment women [DOI] 10.1001/jamanetworkopen.2022.6920 PMC 바로가기 [Article Type] Article